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Biomarkers Unbound — The Supreme Court’s Ruling
on Diagnostic-Test Patents
Aaron S. Kesselheim, M.D., J.D., M.P.H., and Jason Karlawish, M.D.

I

n recent decades, biomarkers have become essential in diagnosing disease and assessing patients’
responses to therapy. The increasing quantitative
rigor and efficiency of these tests have led to the

possibility of “personalized medicine.” Despite such progress, the
way in which a physician uses
biomarkers recapitulates an enduring practice of medicine: measure
the patient, think about the result,
and make a decision.
With these advancements, U.S.
researchers and companies have
also claimed patents on their biomarker discoveries. These patents
have generated controversy over
whether they hinder the practice
of medicine and research by covering not just the actual test but
also the use of the biomarker
generally in making diagnoses
and discovering new applications.
This year, a lawsuit over one such

patent reached the Supreme Court
in Mayo Collaborative Services v. Prometheus Laboratories,1 the outcome
of which may substantially alter
the role of patents in biomarker
discovery and clinical application.
The controversy originated in
the mid-1990s, when researchers
discovered that blood levels of
azathioprine metabolites could
guide the treatment of inflammatory bowel disease. Their patents on their discoveries covered,
among other similar claims, administering azathioprine and measuring the level of a metabolite of
the drug (see diagram): a level below 230 pmol per 8×108 red cells
suggested the need to increase the

10.1056/nejmp1204164

nejm.org

dose, while a level above 400 pmol
per 8×108 red cells suggested the
need to reduce it. The researchers
licensed their patents, including
the one covering this dose-adjustment method, exclusively to Prometheus Laboratories to use in
commercializing a diagnostic test.
Mayo Medical Laboratories initially sent out its specimens to Prometheus for analysis and recommendations that used the patented
correlations. After some time,
however, Mayo’s researchers created what they believed was a
more accurate assay that employed
slightly different cut points for
adjusting azathioprine doses. Mayo
adopted this new assay and
priced it 25% below the price of
Prometheus’s test.2 Prometheus
sued for patent infringement.
U.S. law permits patents for
processes or methods that also
meet the other requirements in
1
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the patent statute, including being novel and “nonobvious,” or entailing a sufficient advance over
existing knowledge. Traditionally,
the primary rule covering whether
a process is patentable was that
the process could not be a law of
nature, such as a mathematical
formula or scientific algorithm.
However, it was permissible to
use a law of nature in an inventive process; in one famous case,
for instance, a patent involved the
use of the Arrhenius equation of
thermodynamics as part of an
inventive process for making synthetic rubber. The Court of Appeals for the Federal Circuit, the
highest patent court below the
Supreme Court, had implemented
this rule by requiring that a process produce a “useful, concrete
and tangible result” in order to be
patentable.
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first reached the
Supreme Court in 2006 in a controversy over a patented process
covering the association between
an elevated blood homocysteine
level and the diagnosis of vitamin B12 or folate deficiencies.3
But the Court ultimately decided
not to hear the case, leaving the
patent intact over a scathing dissent from Justice Stephen Breyer,
who considered this process to
be “a simple natural correlation.”
After that opinion was issued,
the Federal Circuit announced a
new standard for patenting a process: to be distinguished from a
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law of nature, the process must
be related to a machine or cause
a transformation of matter. However, in a 2010 case that unanimously overturned a patent for a
business method for hedging investment risk, the Supreme Court
also narrowly rejected this test as
the sole determinant of patentability, because such a limitation
might improperly exclude future
technology from patenting.4
The Prometheus Laboratories
dispute reached the Court soon
after that ruling was issued. Prometheus argued that its drug–
metabolite correlations were patentable because the process of
identifying the metabolite level,
which led to treatment adjustments, would not occur “but for
the handiwork of man” in creating azathioprine. The U.S. Solicitor General sided with Prometheus
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in principle but argued that these
specific patents might not meet
the tests of novelty or nonobviousness.
But Justice Breyer, this time
writing for a unanimous court,
found the claimed intellectual
property to be an unpatentable
law of nature because it restated a
basic scientific discovery and simply instructed physicians “to gather data from which they may draw
an inference.” The court held
that “if a law of nature is not
patentable, then neither is a process reciting a law of nature,”
and Prometheus’s patent “amounts
to nothing significantly more than
an instruction to doctors to apply
the applicable laws when treating
their patients.”
With this decision, the Supreme
Court has taken a bold step, proscribing patents from covering
correlations used in making biomarker-based diagnoses when
those patents simply describe
“steps that must be taken in order to apply” the natural law in
question. In addition, bundling the
diagnosis with the step of administering a man-made drug does
not make a biomarker discovery
a patentable invention. A patentable process now needs to involve
an inventive and novel application
of a law of nature beyond “wellunderstood, routine, conventional
activity, previously engaged in by
those in the field.”
The Court’s argument would
have applied to the earlier homocysteine case and would also apply to a range of other diagnostic
patents. For example, after Mayo
Collaborative Services, the Federal Circuit must also revisit a lawsuit
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challenging patents held by Myriad
Genetics that cover the BRCA DNA
sequences and the process of using the genes to identify patients
who are at risk for breast cancer.
In light of the decision, the diagnostic patents at issue are not likely to survive. However, it is less
certain whether the more robust
definition of a law of nature laid
out by the Court will extend to
other fields and invalidate the
patents on the essential DNA sequences as well.
Also uncertain is the decision’s
effect on patents covering the use
of a diagnostic method as one
step in a larger process of treating
patients, such as so-called theranostic processes that link biomarkers with safe and effective
drug use. Increasingly, new treatments, especially ones for cancer,
are being codeveloped with biomarker assays that guide their use.
The U.S. Patent Office will now
face the task of distinguishing
the development and characterization of these biomarkers from
other “processes” that simply combine a test for a drug metabolite
with a dosing algorithm.
Excluding some medical discoveries from the possibility of
patenting has led some observers
to worry about the implications
for private investment. Industry
trade groups have argued that
process patents are essential for
recouping the costs of biomarker
innovation. Justice Breyer suggested that Congress could consider
whether innovation in diagnostic
methods needed special marketexclusivity protection. In our view,
a better option would be to increase public funding for bio-
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marker discovery and development. The Foundation for the
National Institutes of Health, an
independent nonprofit organization, has spawned more than
100 projects in this area, including the Biomarkers Consortium, a
public–private partnership investing in the discovery of biomarkers
for Alzheimer’s disease and other
conditions. In genomics, less scientific research and product development have been done on gene
sequences covered by intellectual
property rights than on comparable sequences promulgated
through an open-source model.5
If the Supreme Court’s move to
free the fundamental processes of
medical diagnosis from private
ownership supports greater interest in such consortia, it could ultimately enhance the public health.
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